Cancer immunotherapy using local interleukin 2 administration

This publication has 12 references indexed in Scilit:

• The anti-tumour efficacy of human recombinant interleukin 2
  Cancer Immunology, Immunotherapy, 1987
• Influence of the administration schedule on the therapeutic effect of interleukin-2
  International Journal of Cancer, 1987
• A Progress Report on the Treatment of 157 Patients with Advanced Cancer Using Lymphokine-Activated Killer Cells and Interleukin-2 or High-Dose Interleukin-2 Alone
  New England Journal of Medicine, 1987
• Recombinant interleukin-2 inhibits growth of human tumor xenografts in congenitally athymic mice
  Immunology Letters, 1987
• The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
  The Journal of Immunology, 1986
• Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.
  The Journal of Experimental Medicine, 1985
• Tumour inhibitory effects of TCGF/IL-2/-containing preparations
  Cancer Immunology, Immunotherapy, 1985
• Tumour regression after intralesional injection of interleukin 2 (IL-2) in bladder cancer. Preliminary report
  International Journal of Cancer, 1984
• Growth inhibition of a MC-induced mouse sarcoma by TCGF (IL 2)-containing preparations
  Cancer Immunology, Immunotherapy, 1983
• Solubilized tumour-associated antigens of methyl-cholanthrene-induced mouse sarcomas. Comparative studies byin vitro sensitization of lymph-node cells, macrophage electrophoretic mobility assay and transplantation tests
  International Journal of Cancer, 1978